Compare OMAB & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OMAB | RYTM |
|---|---|---|
| Founded | 1998 | 2008 |
| Country | Mexico | United States |
| Employees | 1326 | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 5.8B |
| IPO Year | N/A | 2017 |
| Metric | OMAB | RYTM |
|---|---|---|
| Price | $111.14 | $85.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | $120.00 | ★ $131.14 |
| AVG Volume (30 Days) | 87.2K | ★ 669.5K |
| Earning Date | 05-08-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.70% | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.36 | $55.34 |
| Revenue Next Year | $13.05 | $86.06 |
| P/E Ratio | $21.86 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $84.74 | $55.31 |
| 52 Week High | $134.99 | $122.20 |
| Indicator | OMAB | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 43.62 | 45.80 |
| Support Level | $110.22 | $82.98 |
| Resistance Level | $114.48 | $90.79 |
| Average True Range (ATR) | 3.14 | 3.46 |
| MACD | -0.07 | 0.21 |
| Stochastic Oscillator | 4.31 | 30.40 |
Grupo Aeroportuario del Centro Norte SAB de CV operates airports in the central region of Mexico. The airport is in Monterrey, which serves nearly half of the company's total passengers. In addition, the company manages two hotels and one industrial park. Its reportable segments include its airports, the Terminal 2 NH Collection Hotel, the Hilton Garden Inn Hotel and the OMA-VYNMSA Industrial Park, individually, and information about its holding company and other companies is combined in the Others.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.